RESEARCH TRIANGLE PARK, N.C. - May 26, 1999 - Quintiles Central Nervous System (CNS) Therapeutics has formed a strategic consulting alliance with Best Practice LLC, a leading CNS drug development consulting group, Quintiles Transnational Corp. (Nasdaq: QTRN) announced today.
The alliance is designed to provide customers with streamlined access to the resources and expertise of both organizations. Quintiles CNS Therapeutics is a recognized leader in CNS drug development, having performed more than 350 clinical trials involving 50,000 patients to help pharmaceutical and biotechnology companies develop drugs and devices to treat CNS disorders in psychiatry and neurology.
"The Best Practice group includes some of the most highly recognized thought leaders in the CNS field, most notably in the areas of psychiatric and neuropsychiatric disorders," said Kevin L. Keim, President of Quintiles CNS Therapeutics. "By working with Best Practice, we provide our customers accelerated access to the experience and credibility of key CNS opinion leaders."
Roger E. Meyer, M.D., Chief Executive Officer of Best Practice, said: "With Quintiles CNS drug development and investigator excellence, this alliance gives pharmaceutical and biotechnology companies rapid, one-stop access to CNS thought leadership, clinical trial design and outcomes. These vital elements add value to customers' products as they move quickly and efficiently from the laboratory, through trial and registration, to the marketplace."
Headquartered in Bethesda, Md., Best Practice's founders include Dr. Meyer and the organization's other principals, Frederick K. Goodwin, M.D., Carol A. Tamminga, M.D., and David G. Daniel, M.D. Best Practice includes nearly 30 affiliated clinical researchers with significant expertise in the following clinical areas or methodologies: age-associated memory impairment, alcoholism, Alzheimer's disease, anxiety disorders, assessments standards, biostatistics, child psychiatry, bipolar disorder, depression, drug dependence and smoking cessation, drug-related movement disorders, eating disorders and obesity; functional brain imaging as related to drug development, neuropsychology, obsessive compulsive disorder, pharmacokinetics, schizophrenia, sleep disorders and women's health.
Quintiles Transnational Corp. is the market leader in providing a full range of integrated product development and commercialization solutions to the pharmaceutical, biotechnology and medical device industries. Quintiles also is a leader in the electronic data interchange and healthcare informatics industry and provides healthcare policy consulting to governments and other organizations worldwide.
Headquartered near Research Triangle Park, North Carolina, Quintiles is a Forbes Platinum 400 and Fortune 1000 company and a member of the Nasdaq-100 Index. With more than 18,000 employees worldwide and offices in 31 countries, Quintiles operates through specialized work groups dedicated to meeting customers' individual needs.